Tetrahydrobiopterin
Clinical data | |
---|---|
Trade names | Kuvan, Biopten |
Other names | Sapropterin hydrochloride (JAN JP), Sapropterin dihydrochloride (USAN US) |
AHFS/Drugs.com | Monograph |
MedlinePlus | a608020 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Elimination half-life | 4 hours (healthy adults) 6–7 hours (PKU patients) |
Identifiers | |
| |
JSmol) | |
| |
| |
(what is this?) (verify) |
Tetrahydrobiopterin (BH4, THB), also known as sapropterin (INN),
Medical use
Tetrahydrobiopterin is available as a tablet for
Sapropterin is indicated in
Adverse effects
The most common
Interactions
No interaction studies have been conducted. Because of its mechanism, tetrahydrobiopterin might interact with
Functions
Tetrahydrobiopterin has multiple roles in human biochemistry. The major one is to convert amino acids such as phenylalanine, tyrosine, and tryptophan to precursors of dopamine and serotonin, major
Cofactor for tryptophan hydroxylases
Tetrahydrobiopterin is a cofactor for
Cofactor for phenylalanine hydroxylase
Cofactor for tyrosine hydroxylase
Cofactor for nitric oxide synthase
Cofactor for ether lipid oxidase
Ether lipid oxidase (alkylglycerol monooxygenase, AGMO) catalyses the conversion of 1-alkyl-sn-glycerol to 1-hydroxyalkyl-sn-glycerol.
History
Tetrahydrobiopterin was discovered to play a role as an enzymatic cofactor. The first enzyme found to use tetrahydrobiopterin is phenylalanine hydroxylase (PAH).[24]
Biosynthesis and recycling
Tetrahydrobiopterin is biosynthesized from
BH4 can be oxidized by one or two electron reactions, to generate BH4 or BH3 radical and BH2, respectively. Research shows that ascorbic acid (also known as ascorbate or
Folic acid and its metabolites seem to be particularly important in the recycling of BH4 and NOS coupling.[28]
Research
Other than PKU studies, tetrahydrobiopterin has participated in clinical trials studying other approaches to solving conditions resultant from a deficiency of tetrahydrobiopterin. These include
Depression
In psychiatry, tetrahydrobiopterin has been hypothesized to be involved in the pathophysiology of depression, although evidence is inconclusive to date.[33]
Autism
In 1997, a small pilot study was published on the efficacy of tetrahydrobiopterin (BH4) on relieving the symptoms of autism, which concluded that it "might be useful for a subgroup of children with autism" and that double-blind trials are needed, as are trials which measure outcomes over a longer period of time.[34] In 2010, Frye et al. published a paper which concluded that it was safe, and also noted that "several clinical trials have suggested that treatment with BH4 improves ASD symptomatology in some individuals."[35]
Cardiovascular disease
Since
Neuroprotection in prenatal hypoxia
Depletion of tetrahydrobiopterin occurs in the hypoxic brain and leads to toxin production. Preclinical studies in mice reveal that treatment with oral tetrahydrobiopterin therapy mitigates the toxic effects of hypoxia on the developing brain, specifically improving white matter development in hypoxic animals.[40]
Programmed cell death
GTPCH (GCH1) and tetrahydrobiopterin were found to have a secondary role protecting against cell death by ferroptosis in cellular models by limiting the formation of toxic lipid peroxides.[41] Tetrahydrobiopterin acts as a potent, diffusable antioxidant that resists oxidative stress[42] and enables cancer cell survival via promotion of angiogenesis.[43]
References
- ^ "Sapropterin (Kuvan) Use During Pregnancy". Drugs.com. 17 May 2019. Retrieved 4 March 2020.
- ^ a b "Kuvan Product information". Health Canada. 25 April 2012. Retrieved 24 June 2022.
- ^ a b c "Kuvan- sapropterin dihydrochloride tablet Kuvan- sapropterin dihydrochloride powder, for solution Kuvan- sapropterin dihydrochloride powder, for solution". DailyMed. 13 December 2019. Retrieved 4 March 2020.
- ^ a b c d "Kuvan EPAR". European Medicines Agency (EMA). 4 March 2020. Retrieved 4 March 2020.
- ^ "Sapropterin". Drugs.com. 28 February 2020. Retrieved 4 March 2020.
- ^ "International Non-proprietary Names for Pharmaceutical Substances (INN)". Fimea. Retrieved 4 March 2020.
- ^ PMID 11848840.
- ^ Cavaleri et al. Blood concentrations of neopterin and biopterin in subjects with depression: A systematic review and meta-analysis Progress in Neuro-Psychopharmacology and Biological Psychiatry 2023. 120:110633. http://dx.doi.org/10.1016/j.pnpbp.2022.110633
- PMID 16584085.
- ISBN 978-0-12-416687-5.
- PMID 708106.
- ^ "Drug Approval Package: Kuvan (Sapropterin Dihydrochloride) NDA #022181". U.S. Food and Drug Administration (FDA). 24 March 2008. Retrieved 4 March 2020.
- Lay summary in: Daniel A. Shames (13 December 2007). "Summary Review: Application number: 22-181" (PDF). U.S. Food and Drug Administration.
- ^ a b c d "Kuvan (sapropterin dihydrochloride) Tablets and Powder for Oral Solution for PKU". BioMarin. Retrieved 4 March 2020.
- ^ "Drug Approval Package: Kuvan Powder for Oral Solution (Sapropterin Dihydrochloride) NDA #205065". U.S. Food and Drug Administration (FDA). 28 February 2014. Retrieved 4 March 2020.
- ^ Herper M (28 July 2016). "How Focusing On Obscure Diseases Made BioMarin A $15 Billion Company". Forbes. Retrieved 9 October 2017.
- ^ "BioMarin Announces Kuvan (sapropterin dihydrochloride) Patent Challenge Settlement". BioMarin Pharmaceutical Inc. 13 April 2017. Retrieved 9 October 2017 – via PR Newswire.
- ^ "Tetrahydrobiopterin Deficiency". National Organization for Rare Disorders (NORD). Retrieved 9 October 2017.
- ^ "What are common treatments for phenylketonuria (PKU)?". NICHD. 23 August 2013. Retrieved 12 September 2016.
- PMID 24667081.
- ^ a b Haberfeld, H, ed. (1 March 2017). Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag. Kuvan 100 mg-Tabletten.
- ^ Cavaleri et al. Blood concentrations of neopterin and biopterin in subjects with depression: A systematic review and meta-analysis Progress in Neuro-Psychopharmacology and Biological Psychiatry 2023. 120:110633. http://dx.doi.org/10.1016/j.pnpbp.2022.110633
- ^ "Genetics Home Reference: GCH1". National Institutes of Health.
- S2CID 29828656.
- PMID 13525410.
- PMID 10727395.
- PMID 12692136.
- PMID 19744948.
- PMID 11535566.
- ^ Cavaleri et al. Blood concentrations of neopterin and biopterin in subjects with depression: A systematic review and meta-analysis Progress in Neuro-Psychopharmacology and Biological Psychiatry 2023. 120:110633. http://dx.doi.org/10.1016/j.pnpbp.2022.110633
- ^ "Search results for Kuvan". ClinicalTrials.gov. U.S. National Library of Medicine.
- ^ "BioMarin Initiates Phase 3b Study to Evaluate the Effects of Kuvan on Neurophychiatric Symptoms in Subjects with PKU". BioMarin Pharmaceutical Inc. 17 August 2010.
- PMID 25533024.
- ^ Cavaleri et al. Blood concentrations of neopterin and biopterin in subjects with depression: A systematic review and meta-analysis Progress in Neuro-Psychopharmacology and Biological Psychiatry 2023. 120:110633. http://dx.doi.org/10.1016/j.pnpbp.2022.110633
- S2CID 12761124.
- PMID 20643376.
- PMID 15596110.
- PMID 12952921.
- PMID 15824200.
- PMID 22315282.
- PMID 31331224.
- PMID 31989025.
- PMID 32778843.
- PMID 20847284.
Further reading
- "Clinical Review Report: Sapropterin dihydrochloride (Kuvan)". CADTH Common Drug Reviews. Ottawa, Canada: PMID 30462435. Bookshelf ID: NBK533813.
- Blau N (June 2016). "Genetics of Phenylketonuria: Then and Now". Human Mutation. 37 (6): 508–15. PMID 26919687.
- Dubois EA, Cohen AF (June 2010). "Sapropterin". British Journal of Clinical Pharmacology. 69 (6): 576–7. PMID 20565448.
- Muntau AC, Adams DJ, Bélanger-Quintana A, Bushueva TV, Cerone R, Chien YH, et al. (May 2019). "International best practice for the evaluation of responsiveness to sapropterin dihydrochloride in patients with phenylketonuria". Molecular Genetics and Metabolism. 127 (1): 1–11. PMID 31103398.
- Qu J, Yang T, Wang E, Li M, Chen C, Ma L, et al. (May 2019). "Efficacy and safety of sapropterin dihydrochloride in patients with phenylketonuria: A meta-analysis of randomized controlled trials". British Journal of Clinical Pharmacology. 85 (5): 893–899. PMID 30720885.
- van Wegberg AM, MacDonald A, Ahring K, Bélanger-Quintana A, Blau N, Bosch AM, et al. (October 2017). "The complete European guidelines on phenylketonuria: diagnosis and treatment". Orphanet Journal of Rare Diseases. 12 (1): 162. PMID 29025426.
External links
- "Sapropterin". Drug Information Portal. U.S. National Library of Medicine.
- "Sapropterin dihydrochloride". Drug Information Portal. U.S. National Library of Medicine.